SPOTLIGHT MYELOMA Trademark

Trademark Overview


On Thursday, March 1, 2018, a trademark application was filed for SPOTLIGHT MYELOMA with the United States Patent and Trademark Office. The USPTO has given the SPOTLIGHT MYELOMA trademark a serial number of 87816031. The federal status of this trademark filing is ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE as of Friday, January 3, 2020. This trademark is owned by Amgen Inc.. The SPOTLIGHT MYELOMA trademark is filed in the Education & Entertainment Services and Medical & Beauty Services & Agricultural Services categories with the following description:

Arranging and conducting educational conferences, seminars and workshops in the fields of multiple myeloma and pharmaceuticals for the treatment of multiple myeloma; providing online publications in the nature of e-books, newsletters, brochures, pamphlets and magazines in the fields of multiple myeloma and pharmaceuticals for the treatment of multiple myeloma

Providing medical information and patient support services, namely, pharmaceutical advice and consultation in the nature of providing online information regarding pharmaceuticals for the treatment of multiple myeloma; providing health and medical information about multiple myeloma and pharmaceuticals for the treatment of multiple myeloma; information services, namely, providing medical information to patients in the fields of multiple myeloma and pharmaceuticals for the treatment of multiple myeloma; providing medical consultancy and advisory services via a global computer network in the fields of multiple myeloma and pharmaceuticals for the treatment of multiple myeloma
spotlight myeloma

General Information


Serial Number87816031
Word MarkSPOTLIGHT MYELOMA
Filing DateThursday, March 1, 2018
Status602 - ABANDONED - FAILURE TO RESPOND OR LATE RESPONSE
Status DateFriday, January 3, 2020
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements


Disclaimer with Predetermined Text"MYELOMA"
Goods and ServicesArranging and conducting educational conferences, seminars and workshops in the fields of multiple myeloma and pharmaceuticals for the treatment of multiple myeloma; providing online publications in the nature of e-books, newsletters, brochures, pamphlets and magazines in the fields of multiple myeloma and pharmaceuticals for the treatment of multiple myeloma
Goods and ServicesProviding medical information and patient support services, namely, pharmaceutical advice and consultation in the nature of providing online information regarding pharmaceuticals for the treatment of multiple myeloma; providing health and medical information about multiple myeloma and pharmaceuticals for the treatment of multiple myeloma; information services, namely, providing medical information to patients in the fields of multiple myeloma and pharmaceuticals for the treatment of multiple myeloma; providing medical consultancy and advisory services via a global computer network in the fields of multiple myeloma and pharmaceuticals for the treatment of multiple myeloma

Classification Information


International Class041 - Education; providing of training; entertainment; sporting and cultural activities.
US Class Codes100, 101, 107
Class Status Code6 - Active
Class Status DateThursday, March 8, 2018
Primary Code041
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

International Class044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateThursday, March 8, 2018
Primary Code044
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameAmgen Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressThousand Oaks, CA 913201799

Trademark Events


Event DateEvent Description
Friday, January 3, 2020ABANDONMENT NOTICE E-MAILED - FAILURE TO RESPOND
Friday, January 3, 2020ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE
Wednesday, June 5, 2019NOTIFICATION OF FINAL REFUSAL EMAILED
Wednesday, June 5, 2019FINAL REFUSAL E-MAILED
Wednesday, June 5, 2019FINAL REFUSAL WRITTEN
Thursday, May 16, 2019TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, May 16, 2019CORRESPONDENCE RECEIVED IN LAW OFFICE
Thursday, May 16, 2019TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, March 7, 2019ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Thursday, March 7, 2019TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, November 16, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, November 16, 2018NON-FINAL ACTION E-MAILED
Friday, November 16, 2018NON-FINAL ACTION WRITTEN
Thursday, October 25, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Wednesday, October 24, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, October 24, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Monday, April 30, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Monday, April 30, 2018NON-FINAL ACTION E-MAILED
Monday, April 30, 2018NON-FINAL ACTION WRITTEN
Friday, April 27, 2018ASSIGNED TO EXAMINER
Thursday, March 8, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM
Monday, March 5, 2018NEW APPLICATION ENTERED IN TRAM